Zimbabwe has rejected a substantial US healthcare agreement valued at $367m (£272m) over five years over the United States' request for sensitive biological samples.
This move came to light after a internal memorandum dated December was disclosed, which showed President Emmerson Mnangagwa believed the deal was "skewed".
A government spokesman later clarified that the US was requesting health data for research and commercial purposes but refused to share the benefits from future vaccines.
"We must now begin the difficult and regrettable process of winding down our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had furnished over $1.9bn for health programmes to Zimbabwe over the last two decades.
A medical body in Zimbabwe has appealed for further talks to reach a deal acceptable to all parties so the nation's vital HIV treatment initiative can be sustained.
Broader Context
This development follows a comparable situation in Kenya, where a high court blocked a similar deal with the US after concerns were filed about the safety of Kenyans' health data.
Since returning to office last year, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
USAID had managed assistance for the US government, but Trump claimed its expenditure was "wasteful" and his administration was seeking direct bilateral deals to boost openness and responsibility.
Based on statements, Sixteen African countries have to date signed these new agreements, constituting more than $18.3bn in committed funds.
Details of the Rejected Agreement
The funds for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this cooperation might have yielded extraordinary benefits for Zimbabwean communities, particularly the 1.2 million presently receiving HIV treatment through US-supported programmes," Tremont said.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"Our nation was requested to surrender its biological resources and data for a long time, without any corresponding guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that shared data," he stated.
"Put simply, our nation would provide the raw materials for scientific discovery without any assurance that the final treatments would be accessible to our people if a future pandemic emerge."
National Interest and Global Health
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were disrupting structures already established through the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing scheme designed to deal with potential pandemics.
"This system is designed to guarantee that when a nation contributes its information, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to develop them."
The government's concerns over the US deal "are not meant as anti-American sentiment," he added.
"We welcome continued dialogue with our American counterparts on how future collaboration might be arranged in a way that honours the sovereignty and interests of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but urged that negotiations need to persist given that much of the nation's Aids initiatives were funded by external financing.
"If technical issues exist, such as those involving information security or implementation frameworks, these can often be addressed through technical clarification and mutually agreed protections," the group commented.
The situation emphasises the complex tensions between receiving vital international aid and protecting national sovereignty in an increasingly interconnected world.